Neos Therapeutics to Participate in Two December Conferences
November 28, 2017 08:00 ET
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Nov. 28, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing, and commercializing innovative...
Neos Therapeutics Reports Third Quarter 2017 Financial Results
November 08, 2017 07:00 ET
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
Neos Therapeutics to Present at the Stifel 2017 Healthcare Conference
November 07, 2017 08:00 ET
|
Neos Therapeutics, Inc.
DALLAS/FORT WORTH, Texas, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing, and commercializing innovative...
Neos Therapeutics to Present Two Posters on Company’s ADHD Medications at the American Academy of Child & Adolescent Psychiatry Meeting
October 24, 2017 16:21 ET
|
Neos Therapeutics, Inc.
DALLAS/FORT WORTH, Texas, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS) today announced that it will present two posters at the 64th Annual Meeting of the American Academy...
Neos Therapeutics Announces Settlement with Actavis on Adzenys XR-ODT® Patent Litigation
October 18, 2017 08:00 ET
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing, and commercializing innovative...
Neos Therapeutics Announces US Launch of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old
October 02, 2017 08:00 ET
|
Neos Therapeutics, Inc
DALLAS/FORT WORTH, Texas, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
Neos Therapeutics Receives U.S. FDA Approval of Adzenys ER™ (amphetamine) Extended-Release Oral Suspension for the Treatment of ADHD in Patients 6 Years and Older
September 15, 2017 16:39 ET
|
Neos Therapeutics, Inc
DALLAS and FORT WORTH, Texas, Sept. 15, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
Neos Therapeutics Announces Launch of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old
September 05, 2017 08:00 ET
|
Neos Therapeutics, Inc
DALLAS and FORT WORTH, Texas, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
Neos Therapeutics Reports Second Quarter 2017 Financial Results
August 08, 2017 07:00 ET
|
Neos Therapeutics, Inc
DALLAS and FORT WORTH, Texas, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
Neos Therapeutics to Host Second Quarter 2017 Financial Results Conference Call on August 8, 2017
August 02, 2017 07:30 ET
|
Neos Therapeutics, Inc
DALLAS and FORT WORTH, Texas, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...